- Details
- In this conversation, Alicia Morgans and Oliver Sartor discuss the safety and efficacy data from the RALU study where patients with metastatic castration-resistant prostate cancer received lutetium-177-prostate-specific membrane antigen (PSMA) with prior radium-223 treatment. The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-p...
|
- Details
- In this conversation, Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer in January 2020. He was initially treated for metastatic hormone-sensitive prostate cancer with enzalutamide plus ADT. He presents again now with progression of bone-only metastatic disease. Drs Shore, Koo, and Morgans talk through...
|
- Details
- Neal Shore and Alicia Morgans discuss the complex landscape of integrating radioligand therapies into the treatment paradigms for metastatic castration-resistant prostate cancer (mCRPC), and nuances around the multidisciplinary administration of radium-223. In evaluating how to best optimize patient care, they reflect on the currently approved life-prolonging therapies, novel mechanisms, and the d...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...
|
- Details
- In this discussion, Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases treated with radium-223 (Ra-223) in the global real-world REASSURE study. REASSURE is evaluating the long-term safety of Radium 223 in routine clinical practice in...
|
- Details
- In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...
|
- Details
- Charles Ryan and Clayton Yates delve into the intricate landscape of health disparities and global health equity. Central to the discussion is Dr. Yates's groundbreaking work as principal investigator of MET-PAAM, studying the molecular mechanisms of tumor progression in metastatic prostate cancer among men of African descent. Dr. Yates provides insights into the unique BRCA2 gene variants found i...
|
- Details
- In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...
|
- Details
- Alicia Morgans converses with Neeraj Agarwal about the ongoing phase III Contact-02 Trial, designed for patients with metastatic castrate-resistant prostate cancer (CRPC) who show disease progression on a novel hormonal therapy or androgen receptor inhibitor. Patients eligible for this trial should have measurable disease, which may include extra pelvic lymphadenopathy or visceral metastasis. Dr....
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
